Everything below concerns prothymosin alpha. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-22. Numbers and descriptions here follow the published literature rather than marketing material.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
=== Suppression of the pro-Alid groups === Mu'awiya died in 680 and was succeeded by his son Yazid I. Mu'awiya's designation of his son was an unprecedented act and shocked many in the Muslim community, particularly the Arab nobility of Kufa. They long sympathized with Caliph Ali, Mu'awiya's former rival, and Ali's family. One of Ali's sons, Husayn dispatched his cousin Muslim ibn Aqil to Kufa to set the stage for Husayn's accession to the caliphate. Ibn Aqil garnered significant support and was hosted by a prominent pro-Alid nobleman. Ubayd Allah became aware of Ibn Aqil's activities, prompting the latter to launch a premature assault against the governor. Ubayd Allah was holed up in his palace, but thirty men from his shurta (security forces) fended off Ibn Aqil's partisans, while he persuaded many Kufan noblemen to back him against Ibn Aqil, who was abandoned by his supporters and slain on 10 September 680. Husayn had already been en route to Kufa from Medina when he received news of Ibn Aqil's execution. Ubayd Allah was prepared for Husayn's arrival and sent troops to intercept him. They prevented Husayn and his small retinue from reaching the watered areas of the province. The two sides negotiated for weeks, but Ubayd Allah refused Husayn entry into Kufa or return to Arabia while Husayn refused to recognize Yazid's caliphate. In the end, a short battle was fought at Karbala on 10 October 680, in which Husayn and nearly all of his partisans were slain.
=== Synthetic alizarin === Natural Alizarin was the first colorant to have its structure determined, making it one of the first targets for synthesis. The first synthesis of alizarin was patented by Carl Graebe and Carl Liebermann in 1868. It entailed the dibromination of anthraquinone, followed by fusion with sodium hydroxide. The second, much cheaper, synthetic path was developed in 1869 by Graebe, Liebermann and Heinrich Caro. It entailed the treatment of anthraquinone with fuming sulphuric acid, followed by a treatment with sodium hydroxide and potassium chlorate. Perkin submitted his own patent for a nearly identical process just a day later, and was awarded the patent in England.
ISBN 978-0-521-89996-3. Tulard, Jean (1984). Napoleon: The Myth of the Saviour. Methuen. ISBN 978-0-416-39510-5. Upshall, Michael, ed. (1993). The Wordsworth Pocket Encyclopedia. Wordsworth Editions. ISBN 978-1-85326-301-9. White, Matthew (2014), Statistics of Wars, Oppressions and Atrocities of the Nineteenth Century, retrieved 3 May 2017. This source references: Bodart, Gaston (1916), Losses of Life in Modern Wars Dumas, Samuel (1923), Losses of Life Caused By War Urlanis, Boris (1971), Wars and Population Payne, Stanley G., A History of Spain and Portugal, vol. 2 Danzer, Arme-Zeitun (in German) Clodfelter, Micheal, Warfare and Armed Conflict: A Statistical Reference to Casualty and Other Figures, 1618–1991 Young, Peter; Lawford, J. P. (2015). Wellington's Masterpiece: The Battle and Campaign of Salamanca. Routledge. ISBN 978-1-317-39728-1.
Glutathione plays a key role in maintaining proper function and preventing oxidative stress in human cells. It can scavenge hydroxyl radicals, singlet oxygen, and various electrophiles. Reduced glutathione reduces the oxidized form of the enzyme glutathione peroxidase, which in turn reduces hydrogen peroxide (H2O2), a dangerously reactive species within the cell. In addition, it plays a key role in the metabolism and clearance of xenobiotics, acts as a cofactor in certain detoxifying enzymes, participates in transport, and regenerates antioxidants such and Vitamins E and C to their reactive forms. The ratio of GSSG/GSH present in the cell is a key factor in properly maintaining the oxidative balance of the cell, that is, it is critical that the cell maintains high levels of the reduced glutathione and a low level of the oxidized glutathione disulfide. This narrow balance is maintained by glutathione reductase, which catalyzes the reduction of GSSG to GSH.
=== Pyrrolidines and Pyrrolidinophenones === Pyrrolidines are amphetamines with a pyrrolidine group. Pyrrolidinophenones (also called Pyrovalerones) are cathinones (βk-amphetamines) with a pyrrolidine group.
Sources: en.wikipedia.org
1970 Establishment of the International Food Irradiation Project (IFIP), headquarters at the Federal Research Centre for Food Preservation, Karlsruhe, Germany 1980 FAO/IAEA/WHO Joint Expert Committee on Food Irradiation recommends the clearance generally up to 10 kGy "overall average dose" 1981/1983 End of IFIP after reaching its goals 1983 Codex Alimentarius General Standard for Irradiated Foods: any food at a maximum "overall average dose" of 10 kGy 1984 International Consultative Group on Food Irradiation (ICGFI) becomes the successor of IFIP 1986 January People's Republic of China opens their first food irradiation facility in Shanghai 1994 India approves irradiation of spices, potato and onion. 1997 FAO/IAEA/WHO Joint Study Group on High-Dose Irradiation recommends to lift any upper dose limit 1998 The European Union's Scientific Committee on Food (SCF) voted in favour of eight categories of irradiation applications 1999 The European Union adopts Directives 1999/2/EC (framework Directive) and 1999/3/EC (implementing Directive) limiting irradiation a positive list whose sole content is one of the eight categories approved by the SCF, but allowing the individual states to give clearances for any food previously approved by the SCF. 2000 Germany leads a veto on a measure to provide a final draft for the positive list. 2003 Codex Alimentarius General Standard for Irradiated Foods: no longer any upper dose limit 2003 The SCF adopts a "revised opinion" that recommends against the cancellation of the upper dose limit.
(which is true for all aqueous solutions), and the constraint that the solution must be electrically neutral, i.e., the overall charge of dissolved positive ions [Ca2+] + 2 [H+] must be cancelled out by the overall charge of dissolved negative ions [HCO−3] + [CO2−3] + [OH−], make it possible to solve simultaneously for the remaining five unknown concentrations (the previously mentioned form of the neutrality is valid only if calcium carbonate has been put in contact with pure water or with a neutral pH solution; in the case where the initial water solvent pH is not neutral, the balance is not neutral). The adjacent table shows the result for [Ca2+] and [H+] (in the form of pH) as a function of ambient partial pressure of CO2 (Ksp = 4.47×10−9 has been taken for the calculation).
=== Underlying cause === PNP is ultimately caused by the presence of a tumor. There is a strong association between the development of PNP and malignancy of the tumor. However, it is not uncommon for the tumor to be benign, as in the case of afflictions such as thymoma and Castleman's disease. Only one patient without a tumor has met the diagnostic criteria for PNP. However, they rapidly reached their demise and it is suggested they may have had an undiagnosed tumor.
== Regulation == Some of the strategies for regulating retinal dehydrogenases are only now becoming more clear after in vivo regulation remained mysterious for some time, though much of the current research on regulation has focused on the modulation of gene expression rather than direct protein regulation. Dendritic cells in the gut help in modulating immune tolerance through the activity of retinal dehydrogenase; expression in these cells may be driven by a TNF receptor, 4-1-BB. It was also shown that the expression of a certain retinal dehydrogenase found in humans, retinal short-chain dehydrogenase/reductase (retSDR1), is increased by tumor-suppressor proteins p53 and p63, suggesting that retSDR1 may have tumor-preventing activities. Expression of retinal dehydrogenase types 1 and 2 genes is enhanced by the addition of cholesterol or cholesterol derivatives. Disulfiram is a drug used to artificially regulate aldehyde dehydrogenase activity in patients with alcoholism by inhibiting the activity of aldehyde dehydrogenases, though it is not specific to retinal dehydrogenase. Other exogenous molecules have also been found to inhibit retinal dehydrogenase activity including nitrofen, 4-biphenyl carboxylic acid, bisdiamine, and SB-210661.
Sources: en.wikipedia.org
== Overview == Scooter's Coffee uses a franchise model to establish new stores. Some locations are drive-through only and do not have sit-in dining areas. The buildings are standardized and measure 664 square feet (61.7 m2). Its coffee is produced by Harvest Roasting, which was founded alongside Scooter's Coffee. The menu includes hot and cold drinks, including coffee, tea, and smoothies; and food items, such as pastries, burritos, and sandwiches. It also has breakfast and kids menus. Its signature drink is the Caramelicious, an espresso drink with caramel sauce and whipped cream.
=== Antibody Epitope Mapping === Antibody epitope mapping is used to find the specificity of an antibody. The epitope (antibody binding site of antigens) is expressed on the bacterial cell surface by expressing a region of the gene encoding the antigen. Flow cytometry with fluorescently-labelled antibodies is used to detect the amount of antibody binding to epitope.
=== Hemolytic effect === Guanacastepene A also exhibits a significant toxic side effect in that it possesses pronounced hemolytic activity, which leads to the lysis of erythrocytes (human red blood cells). The strongest hemolytic effect was observed in laboratory tests at concentrations between 8 and 32 µg/ml. However, this effect diminishes at very high concentrations (above 64 µg/ml) as well as at very low concentrations (below 8 µg/ml). The mechanism of cell membrane damage is not selective enough for bacteria; eukaryotic cell membranes are also affected by the damaging effect of Guanacastepene A.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.